Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery
Completed
Conditions studied: Thrombosis
In brief
Heparin is a drug that is widely used to prevent and treat blood clotting. Individuals undergoing cardiopulmonary bypass surgery are administered high doses of heparin, and some of them develop antibodies to the drug. This immune response can lead to the formation of blood clots, setting the stage for a potential heart attack or stroke. The purpose of this study is to evaluate how often an immune response to heparin leads to the formation of blood clots in individuals who have had heart surgery.
Key facts
- Study ID
- NCT00237328
- Run by
- Duke University
- People needed
- 1015
- Starts
- 2006-06-01
- Expected to finish
- 2012-07-01
- Last updated by the study team
- 2013-02-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Scheduled for cardiac bypass surgery at Duke University Hospital
You may not qualify if…
- Plans to receive warfarin during the post-operative inpatient stay
- Plans to receive a full anticoagulant dose of low-molecular weight heparin during the post-operative inpatient stay
- Plans to receive a full anticoagulant dose of unfractionated heparin during the post-operative inpatient stay
- Use of any drug other than unfractionated heparin for anticoagulation during cardiopulmonary bypass
- Warfarin, heparin, or low-molecular weight heparin administered during a readmission to the hospital for a reason other than one of this study's outcomes does not constitute criteria for exclusion
Where it is running
- Mayo Clinic, Rochester — Rochester, Minnesota, United States
- University of North Carolina — Chapel Hill, North Carolina, United States
- Duke University Medical Center — Durham, North Carolina, United States
- University of Wisconsin — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.